Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
4,004
Views
6
CrossRef citations to date
0
Altmetric
Nephrology

Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Adrian R. Levya Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8966-0966
ORCID Icon,
Peter Chenb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-2015-9943
ORCID Icon,
Karissa Johnstonc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0003-4570-9972
ORCID Icon,
Yan Wangb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-9578-4781
ORCID Icon,
Evan Popoffc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-3233-3147
ORCID Icon &
Ioannis Tomazosb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-0290-4583
ORCID Icon
Pages 249-259 | Received 30 Sep 2021, Accepted 07 Jan 2022, Published online: 17 Feb 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.